|
시장보고서
상품코드
2008022
만성 특발성 두드러기(CSU) 시장 : 약제 클래스별, 유형별, 제형별, 투여 경로별, 연령별, 판매 채널별, 지역별Chronic Spontaneous Urticaria Market, By Drug Class, By Type, By Form, By Route of Administration, By Age, By Distribution Channel, By Geography |
||||||
만성 특발성 두드러기(CSU) 시장은 2026년에 30억 6,410만 달러로 추정되고 있으며, 2033년까지 46억 5,710만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 9%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 30억 6,410만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 9.00% | 2033년 시장 규모 예측 : | 46억 5,710만 달러 |
세계의 만성 특발성 두드러기(CSU) 시장 규모는 6주 이상 지속되는 부종, 혈관성 부종 또는 이 두 가지 모두에 대한 외부적 요인이 없음에도 불구하고 자연적으로 발생하는 것을 특징으로 하는 복잡한 피부 질환을 의미합니다.
이 쇠약하게 만드는 질병은 전 세계 인구의 약 0.5-1%가 앓고 있으며, 30-50세 성인, 특히 여성에서 높은 유병률이 관찰되고 있습니다. 만성 특발성 두드러기(CSU)의 병태생리에는 면역학적 및 비면역학적 경로를 통한 비만 세포의 탈과립과 히스타민 방출이 관여하여 심한 가려움증, 부종 및 염증성 피부 병변과 같은 특징적인 증상을 유발하여 환자의 삶의 질에 심각한 영향을 미칩니다.
세계의 만성 특발성 두드러기(CSU) 시장은 1차 선택약물인 항히스타민제부터 첨단 생물제제 및 면역억제제까지 다양한 치료법을 포함하고 있습니다. 근본적인 메커니즘에 대한 이해의 발전으로 표적치료제, 특히 오말리주맙과 새로운 생물제제가 개발되어 치료 패러다임에 혁명을 일으켰습니다.
이러한 시장 환경은 질병에 대한 인식의 증가, 진단 능력의 향상, 의료비 증가, 효과적인 장기 관리 솔루션에 대한 수요 증가에 의해 주도되고 있습니다. 의료진은 국제 가이드라인에서 권장하는 단계적 치료 접근법을 점점 더 많이 채택하고 있으며, 이는 이 어려운 질환의 미충족 수요를 충족시킬 수 있는 혁신적인 치료 솔루션을 개발하는 데 있으며, 제약회사에 큰 기회를 제공하고 있습니다.
시장 역학
세계의 만성 특발성 두드러기(CSU) 시장은 세계의 자가면역 및 알레르기 질환의 유병률 증가, 만성 특발성 두드러기(CSU) 진단 및 관리에 대한 의료진의 인식 증가, 효과적인 치료 옵션에 대한 환자들의 요구 증가 등 몇 가지 주요 촉진요인에 의해 주도되고 있습니다. 주도하고 있습니다. 바이오의약품, 특히 오말리주맙의 도입은 치료 결과를 크게 개선하고, 높은 가격 책정 및 치료 효과의 향상을 통해 시장 확대를 촉진하고 있습니다.
또한 연구개발 활동에 대한 막대한 투자, 신흥 국가의 의료 인프라 확충, 만성질환에 대한 유리한 상환 정책도 시장 성장에 기여하고 있습니다. 그러나 시장은 몇 가지 눈에 띄는 제약에 직면해 있습니다. 특히 가격에 민감한 시장에서 접근성을 제한하는 고가의 생물제제 치료제의 높은 비용, 의약품 승인에 대한 엄격한 규제 요건, 면역억제 치료에 따른 잠재적 부작용 등 다양한 제약요인이 있습니다. 일반 개원의들 사이에서 CSU 관리 가이드라인에 대한 인식이 부족하고, 다른 두드러기 질환과의 감별 진단이 어렵다는 점도 시장 침투에 걸림돌로 작용하고 있습니다.
또한 훨씬 저렴한 제네릭 항히스타민제의 출시로 인해 혁신적인 치료법에 대한 가격 압박이 발생하고 있습니다. 이러한 어려움에도 불구하고 시장에는 특히 기존 항히스타민제 치료에도 증상이 지속되는 환자들을 포함하여 적절한 치료를 받지 못하는 환자들이 다수 존재하므로 큰 기회가 존재합니다. 항IgE 항체, 보체 억제제, 비만세포 안정화제 등 새로운 치료 표적의 개발은 시장 확대를 위한 유망한 경로를 보여주고 있습니다. 아시아태평양과 라틴아메리카의 신흥 시장에서는 의료 접근성 향상, 가처분 소득 증가, 질병에 대한 인식 증가로 인해 미개발된 잠재력이 존재합니다. 한편, 디지털 헬스 솔루션과 원격의료 플랫폼은 환자와의 소통과 치료 과정을 모니터링할 수 있는 새로운 채널을 창출하고 있습니다.
본 조사의 주요 특징.
- 세계의 만성 특발성 두드러기(CSU) 시장에 대한 상세한 분석을 제공하며, 2025년을 기준연도로 하여 예측 기간(2026-2033년) 시장 규모와 예측 기간(2026-2033년)의 CAGR(%)을 조사하여 전해드립니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 이 보고서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계의 만성 특발성 두드러기(CSU) 시장의 주요 기업 개요을 분석합니다. : 회사 개요, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 만성 특발성 두드러기(CSU) 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 만성 특발성 두드러기(CSU) 시장 : 약제 클래스별, 2021-2033년
제5장 세계의 만성 특발성 두드러기(CSU) 시장 : 유형별, 2021-2033년
제6장 세계의 만성 특발성 두드러기(CSU) 시장 : 제형별, 2021-2033년
제7장 세계의 만성 특발성 두드러기(CSU) 시장 : 투여 경로별, 2021-2033년
제8장 세계의 만성 특발성 두드러기(CSU) 시장 : 연령별, 2021-2033년
제9장 세계의 만성 특발성 두드러기(CSU) 시장 : 유통 채널별, 2021-2033년
제10장 세계의 만성 특발성 두드러기(CSU) 시장 : 지역별, 2021-2033년
제11장 경쟁 구도
제12장 애널리스트의 추천
제13장 참고 문헌 및 조사 방법
KSA 26.04.30Chronic Spontaneous Urticaria Market is estimated to be valued at USD 3,064.1 Mn in 2026 and is expected to reach USD 4,657.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,064.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.00% | 2033 Value Projection: | USD 4,657.1 Mn |
Global chronic spontaneous urticaria market represents a complex dermatological condition characterized by the spontaneous appearance of wheals, angioedema, or both for a period exceeding six weeks without an identifiable external trigger.
This debilitating condition affects approximately 0.5-1% of the global population, with a higher prevalence observed in adults between 30-50 years of age, particularly women. The pathophysiology of chronic spontaneous urticaria (CSU) involves mast cell degranulation and histamine release through both immunological and non-immunological pathways, leading to characteristic symptoms including intense pruritus, swelling, and inflammatory skin lesions that significantly impact patients' quality of life.
The global chronic spontaneous urticaria market encompasses various therapeutic interventions ranging from first-line antihistamines to advanced biologics and immunosuppressive agents. Recent advances in understanding the underlying mechanisms have led to the development of targeted therapies, particularly omalizumab and emerging biologics, which have revolutionized treatment paradigms.
The market landscape is driven by increasing disease awareness, improved diagnostic capabilities, rising healthcare expenditure, and growing demand for effective long-term management solutions. Healthcare providers are increasingly adopting step-wise treatment approaches as recommended by international guidelines, creating substantial opportunities for pharmaceutical companies to develop innovative therapeutic solutions addressing unmet medical needs in this challenging condition.
Market Dynamics
The global chronic spontaneous urticaria market is propelled by several key drivers including the rising prevalence of autoimmune and allergic disorders worldwide, increased awareness among healthcare professionals regarding Chronic Spontaneous Urticaria (CSU) diagnosis and management, and growing patient advocacy for effective treatment options. The introduction of biologics, particularly omalizumab, has significantly transformed treatment outcomes, driving market expansion through premium pricing and improved therapeutic efficacy.
Additionally, substantial investments in research and development activities, expanding healthcare infrastructure in emerging economies, and favorable reimbursement policies for chronic conditions contribute to market growth. However, the market faces notable restraints including the high cost of advanced biologic therapies, which limits accessibility particularly in price-sensitive markets, stringent regulatory requirements for drug approvals, and potential side effects associated with immunosuppressive treatments. Limited awareness among general practitioners regarding CSU management guidelines and the challenge of differential diagnosis from other urticarial conditions further impede the market penetration.
Furthermore, the availability of generic antihistamines at significantly lower costs creates pricing pressure on innovative therapies. Despite these challenges, the market presents substantial opportunities driven by the large population of inadequately treated patients, particularly those who remain symptomatic on conventional antihistamine therapy. The development of novel therapeutic targets, including anti-IgE antibodies, complement inhibitors, and mast cell stabilizers, offers promising avenues for market expansion. Emerging markets in Asia Pacific and Latin America present untapped potential due to improving healthcare access, rising disposable incomes, and increasing disease awareness, while digital health solutions and telemedicine platforms create new channels for patient engagement and treatment monitoring.
Key Features of the Study
- This report provides in-depth analysis of the global chronic spontaneous urticaria market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global chronic spontaneous urticaria market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Sanofi S.A, Regeneron Pharmaceuticals Inc, GlaxoSmithKline plc, Pfizer Inc, Genentech Inc (Roche Group), Merck & Co Inc, Johnson & Johnson Services Inc, AstraZeneca plc, Bayer AG, Teva Pharmaceutical Industries Ltd, AbbVie Inc, Amgen Inc, Sun Pharmaceutical Industries Ltd, and UCB S.A
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global chronic spontaneous urticaria market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic spontaneous urticaria market
Market Segmentation
- Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
- Monoclonal antibodies
- Xolair
- Dupixent
- Antihistamines
- Phase 3 drugs
- Ligelizumab
- Remibrutinib
- Type Insights (Revenue, USD Mn, 2021 - 2033)
- Branded
- Generic
- Form Insights (Revenue, USD Mn, 2021 - 2033)
- Injectable
- Tablets
- Capsules
- Syrup
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Subcutaneous
- Age Insights (Revenue, USD Mn, 2021 - 2033)
- Pediatric
- Adult
- Geriatric
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Sanofi S.A
- Regeneron Pharmaceuticals Inc
- GlaxoSmithKline plc
- Pfizer Inc
- Genentech Inc (Roche Group)
- Merck & Co Inc
- Johnson & Johnson Services Inc
- AstraZeneca plc
- Bayer AG
- Teva Pharmaceutical Industries Ltd
- AbbVie Inc
- Amgen Inc
- Sun Pharmaceutical Industries Ltd
- UCB S.A
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Chronic Spontaneous Urticaria Market, By Drug Class
- Global Chronic Spontaneous Urticaria Market, By Type
- Global Chronic Spontaneous Urticaria Market, By Form
- Global Chronic Spontaneous Urticaria Market, By Route of Administration
- Global Chronic Spontaneous Urticaria Market, By Age
- Global Chronic Spontaneous Urticaria Market, By Distribution Channel
- Global Chronic Spontaneous Urticaria Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Chronic Spontaneous Urticaria Market, By Drug Class, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Monoclonal antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Xoair
- Dupixent
- Antlihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Phase 3 drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Ligelizumab
- Remibrutinib
5. Global Chronic Spontaneous Urticaria Market, By Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Chronic Spontaneous Urticaria Market, By Form, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Syrup
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Chronic Spontaneous Urticaria Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Chronic Spontaneous Urticaria Market, By Age, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. Global Chronic Spontaneous Urticaria Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. Global Chronic Spontaneous Urticaria Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genentech Inc (Roche Group)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson Services Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB S.A
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
